+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neutropenia Biologic Drug Treatment Global Market Report 2022: By Drug, By Treatment, By Distribution

  • PDF Icon

    Report

  • 400 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553675
Neutropenia Biologic Drug Treatment Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global neutropenia biologic drug treatment market.



This report focuses on neutropenia biologic drug treatment market which is experiencing strong growth. The report gives a guide to the neutropenia biologic drug treatment market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the neutropenia biologic drug treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Neutropenia Biologic Drug Treatment market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider neutropenia biologic drug treatment market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
  • The neutropenia biologic drug treatment market section of the report gives context. It compares the neutropenia biologic drug treatment market with other segments of the neutropenia biologic drug treatment market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, neutropenia biologic drug treatment indicators comparison

Scope


Markets Covered:


1) By Drug Type: Filgrastim; Pegfilgrastim; Lenograstim; Lipegfilgrastim; Sargramostim
2) By Treatment Type: Antibiotic Drugs; Granulocyte-Colony-Stimulating Factor (G-CSF); Antifungal Drugs; Others
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies

Companies Mentioned: Teva Pharmaceutical; Amgen; Sanofi; Mylan; Kyowa Kirin

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Frequently Asked Questions about the Global Neutropenia Biologic Drug Treatment Market

What is the estimated value of the Global Neutropenia Biologic Drug Treatment Market?

The Global Neutropenia Biologic Drug Treatment Market was estimated to be valued at $11.3 billion in 2022.

What is the growth rate of the Global Neutropenia Biologic Drug Treatment Market?

The growth rate of the Global Neutropenia Biologic Drug Treatment Market is 7.0%, with an estimated value of $14.8 billion by 2026.

What is the forecasted size of the Global Neutropenia Biologic Drug Treatment Market?

The Global Neutropenia Biologic Drug Treatment Market is estimated to be worth $14.8 billion by 2026.

Who are the key companies in the Global Neutropenia Biologic Drug Treatment Market?

Key companies in the Global Neutropenia Biologic Drug Treatment Market include Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp., Novartis and Partner Therapeutics.

Table of Contents

1. Executive Summary2. Neutropenia Biologic Drug Treatment Market Characteristics3. Neutropenia Biologic Drug Treatment Market Trends And Strategies4. Impact Of COVID-19 On Neutropenia Biologic Drug Treatment
5. Neutropenia Biologic Drug Treatment Market Size And Growth
5.1. Global Neutropenia Biologic Drug Treatment Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Neutropenia Biologic Drug Treatment Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Neutropenia Biologic Drug Treatment Market Segmentation
6.1. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Filgrastim
  • Pegfilgrastim
  • Lenograstim
  • Lipegfilgrastim
  • Sargramostim
6.2. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Antibiotic Drugs
  • Granulocyte-Colony-Stimulating Factor (G-CSF)
  • Antifungal Drugs
  • Others
6.3. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

7. Neutropenia Biologic Drug Treatment Market Regional And Country Analysis
7.1. Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Neutropenia Biologic Drug Treatment Market
8.1. Asia-Pacific Neutropenia Biologic Drug Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Neutropenia Biologic Drug Treatment Market
9.1. China Neutropenia Biologic Drug Treatment Market Overview
9.2. China Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Neutropenia Biologic Drug Treatment Market
10.1. India Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Neutropenia Biologic Drug Treatment Market
11.1. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Neutropenia Biologic Drug Treatment Market
12.1. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Neutropenia Biologic Drug Treatment Market
13.1. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Neutropenia Biologic Drug Treatment Market
14.1. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Neutropenia Biologic Drug Treatment Market
15.1. Western Europe Neutropenia Biologic Drug Treatment Market Overview
15.2. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Neutropenia Biologic Drug Treatment Market
16.1. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Neutropenia Biologic Drug Treatment Market
17.1. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Neutropenia Biologic Drug Treatment Market
18.4. France Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Neutropenia Biologic Drug Treatment Market
19.1. Eastern Europe Neutropenia Biologic Drug Treatment Market Overview
19.2. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Neutropenia Biologic Drug Treatment Market
20.1. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Neutropenia Biologic Drug Treatment Market
21.1. North America Neutropenia Biologic Drug Treatment Market Overview
21.2. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Neutropenia Biologic Drug Treatment Market
22.1. USA Neutropenia Biologic Drug Treatment Market Overview
22.2. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Neutropenia Biologic Drug Treatment Market
23.1. South America Neutropenia Biologic Drug Treatment Market Overview
23.2. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Neutropenia Biologic Drug Treatment Market
24.1. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Neutropenia Biologic Drug Treatment Market
25.1. Middle East Neutropenia Biologic Drug Treatment Market Overview
25.2. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Neutropenia Biologic Drug Treatment Market
26.1. Africa Neutropenia Biologic Drug Treatment Market Overview
26.2. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Neutropenia Biologic Drug Treatment Market Competitive Landscape And Company Profiles
27.1. Neutropenia Biologic Drug Treatment Market Competitive Landscape
27.2. Neutropenia Biologic Drug Treatment Market Company Profiles
27.2.1. Teva Pharmaceutical
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Amgen
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Sanofi
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Mylan
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Kyowa Kirin
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Neutropenia Biologic Drug Treatment Pipeline Analysis29. Key Mergers And Acquisitions In The Neutropenia Biologic Drug Treatment Market30. Neutropenia Biologic Drug Treatment Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp., Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.

The global neutropenia biologic drug treatment market is expected to grow from $10.22 billion in 2021 to $11.26 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $14.78 billion in 2026 at a CAGR of 7.0%.

The neutropenia biologic drug treatment market consists of sales of biologics used for the treatment of neutropenia and related services by entities (organizations, sole traders and partnerships) that produce biologics for neutropenia treatment. Neutropenia is a clinical condition characterized by a decrease in neutrophil count in the blood, resulting in a higher risk of developing serious infections. A neutrophil is a type of white blood cell, which helps in fighting infections. The major causes of neutropenia include cancer chemotherapy, infections, bone marrow disorders, autoimmune disorders, and the use of specific drugs. The market consists of revenue generated by the company’s manufacturing the neutropenia biologic drugs by the sales of these products.

The main types of drugs in neutropenia biologic drug treatment are filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim and sargramostim. Filgrastim is a recombinant form of granulocyte colony-stimulating protein which is given as an injection to boost neutrophil production after chemotherapy. The different types of treatments include antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, others and distributed through various channels such as retail pharmacies, hospital pharmacies, online pharmacies.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the neutropenia biologic drugs market. Due to a growing cancer incidence and an increase in the number of people opting for chemotherapy, there has been an increasing incidence in the number of people suffering from neutropenia. According to a 2019 study by Cancer.net, around 50% of the people with cancer who are undergoing chemotherapy have some level of neutropenia. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the neutropenia biologic drug treatment market over the forthcoming years.

The introduction of biosimilars as a result of patent expiry is expected to hamper the growth of the neutropenia biologic drug treatment market. Biosimilar is a therapeutic agent, which has high similarity with the original biological product in action but is available at a lower cost than the cost of the original product. Biosimilars are mostly priced at 70% of the branded drug price and are likely to replace expensive branded drugs. For instance, Novartis AG launched a biosimilar drug, Zarxio, which has substituted Amgen’s branded biologic drug, Neupogen. These less expensive alternatives increase competition in the biologics market putting downward pressure on pricing and market value growth.

Companies in the neutropenia biologic drug treatment market are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disallowing side-effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells, and is used for treating severe neutrophil-mediated disease.

In September 2020, Gilead Sciences, a US-based biopharmaceutical company launched Immunomedics for $21 billion. Through this acquisition Gilead will get TrodelvyTM ( acituzumab govitecan-hziy), which will alter Gilead’s portfolio by adding a first-in-class commercial drug with considerable revenue potential and best-in-class potential. Immunomedics is a US-based biotechnology company that offers neutropenia biologic drug treatment .

The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Teva Pharmaceutical
  • Amgen
  • Sanofi
  • Mylan
  • Kyowa Kirin
  • Baxter International
  • CVS Health Corp.
  • Novartis
  • Spectrum Pharmaceuticals
  • Partner Therapeutics
  • Pfizer
  • Myelo Therapeutics
  • Cellerant Therapeutics
  • Sandoz (Subsidary of Novartis AG)
  • BeyondSpring Pharmaceuticals
  • Enzychem Lifesciences Corporation
  • Tianjin SinoBiotech
  • S&D Pharma SK s.r.o.
  • Generon (Shanghai) Corporation Ltd.
  • PhytoHealth Corporation
  • Dong-A ST Co.

Methodology

Loading
LOADING...